PSA and Prostate Cancer Screening: The Challenge of the New Millennium

European Urology

Volumn 52, Issue 5, 2007, Pages 1284-1286

  Bjartell, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; EDITORIAL; HUMAN; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548830415     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.026     Document Type: Editorial

References (13)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Shah J.B., Reese A.C., McKiernan J.M., and Benson M.C. PSA updated: still relevant in the new millennium?. Eur Urol 47 (2005) 427-432
3. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
4. Tombal B. Over- and underdiagnosis of prostate cancer: the dangers. Eur Urol Suppl 5 (2005) 511-513
5. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
6. Catalona W.J., and Loeb S. The PSA era is not over for prostate cancer. Eur Urol 48 (2005) 541-545
7. Shariat S.F., Abdel-Aziz K.F., Roehrborn C.G., and Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Eur Urol 49 (2006) 293-302
8. Roddam A.W., Duffy M.J., Hamdy F.C., et al., on behalf of the NHS Prostate Cancer Risk Management Programme. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399
9. Lilja H., Ulmert D., Björk D., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25 (2007) 431-436
10. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
11. Klotz L., and Teahan S. Current role of PSA kinetics in the management of patients with prostate cancer. Eur Urol Suppl 5 (2006) 472-478
12. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 47 (2005) 16-21
13. Aus G., Bergdahl S., Lodding P., Lilja H., and Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 51 (2007) 659-664